Guilford (GLFD) - Steadily Rising Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Guilford (GLFD) - Steadily Rising

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jim Ball who started this subject	7/27/2000 9:19:58 AM
From: sim1	Read Replies (1) of 496

News from Amgen Amgen and its partner Guilford Pharmaceuticals have also advanced the neuroimmunophilin clinical program into phase 2 clinical testing in patients with Parkinson's disease. Parkinson's disease afflicts approximately one million patients in the U.S. and is a condition for which there is a significant unmet medical need. biz.yahoo.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next